Pear Therapeutics announced today that it entered into multiple agreements to bolster its prescription digital therapeutics (PDT) platform.

Boston-based Pear Therapeutics’ agreements are set to add to its library of digital biomarkers, machine learning algorithms, sensor-based technologies and digital therapeutics, according to a news release.

The agreements have been struck with technology companies including Empatica, etectRx and KeyWise as Pear Therapeutics seeks to build a comprehensive product offering for remote sensing, real-time personalization of digital therapeutic content and pharmaceutical dosing and overall enhanced patient outcomes.

Empatica develops medical wearables and digital biomarkers. The agreement will allow Pear to explore using the sensors to evaluate withdrawal symptoms in patients with substance use disorder, opioid use disorder and alcohol use disorder.

The agreement with etectRx will explore the development of digital therapeutics combined with digital pills, using etectRx’s FDA-cleared ID-Cap digital pill system. ID-Cap is an ingestible event marker designed to guide digital, patient-centric and value-based therapeutic interventions.

Finally, the deal with KeyWise is set to help Pear build capabilities to track and produce individualized mental health metrics with natural language processing PDTs through an artificial intelligence-enabled keystroke detection algorithm developed by KeyWise and licensed by Pear.

“We are excited to announce these agreements, which expand the leading PDT platform and create optionality as the space grows beyond neurobehavioral therapies,” Pear president & CEO Dr. Corey McCann said in the release. “Accessing external technologies allows us to build PDTs with new capabilities and continue to broaden their scope and effectiveness. With the ability to collect and quantify information in real-world settings and to potentially personalize products in real-time, PDTs present the opportunity to truly revolutionize healthcare.”